Pedestrians arriving at clearance phase (Flashing Don't Walk) face different levels of risk depending on behavioral choice afterwards. However, few studies have focused on the choices pedestrians make during this phase. This field study analyzed pedestrian choices after arrival, evaluated safety of the choices, and built a model to identify the predictors of pedestrian choices. It was found that pedestrians arriving during clearance phase made dynamic decisions based on the changing contexts. Specifically, the majority made the decision to "cross" as opposed to "wait" (85.2% vs. 14.8% respectively), although only the latter choice is legal. Seventy-nine percent of the pedestrians did not finish crossing the intersection before the traffic light turned red, and they walked 41% of the road width during a red light. For those waited, roughly half of them waited until green or crossed at an intersecting crosswalk, while others finally started on red light. Nevertheless, the waited pedestrians still faced lower risk than those crossed prematurely in terms of running behaviors, and conflicts with vehicles. Pedestrians are more likely to cross immediately after arrival when they are younger, are not engaged in secondary tasks, arrived at a position farther from approaching vehicles at the near side of the road, or arrived at a time when there are more pedestrians crossing the road. Although fewer pedestrians choose to cross when the required speed is higher (due to a wider road or less remaining time), the required speed they choose to cross at is far higher than their actual speed. These findings are essential for realistic pedestrian simulations and targeted safety countermeasures. They also imply the need for changes to certain traffic regulations and signal design to facilitate safe decision making at clearance phase.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.aap.2017.08.019 | DOI Listing |
J Cancer Res Clin Oncol
January 2025
Institute for Community Medicine, Section Epidemiology of Health Care and Community Health, University Medicine Greifswald, 17489, Greifswald, Germany.
Introduction: The objective of this study is to compare the 5 year overall survival of patients with stage I-III colon cancer treated by laparoscopic colectomy versus open colectomy.
Methods: Using Mecklenburg-Western Pomerania Cancer Registry data from 2008 to 2018, we will emulate a phase III, multicenter, open-label, two-parallel-arm hypothetical target trial in adult patients with stage I-III colon cancer who received laparoscopic or open colectomy as an elective treatment. An inverse-probability weighted Royston‒Parmar parametric survival model (RPpsm) will be used to estimate the hazard ratio of laparoscopic versus open surgery after confounding factors are balanced between the two treatment arms.
Polymers (Basel)
January 2025
Facultad de Farmacia-Centro de Innovación en Química Avanzada (ORFEO-CINQA), Unidad nanoDrug, Departamento de Química Inorgánica, Orgánica y Bioquímica, Universidad de Castilla-La Mancha, 02071 Albacete, Albacete, Spain.
The compounds targeting the bromo and extra terminal domain proteins (BET), such as the JQ1, present potent anti-cancer activity in preclinical models, however, the application of JQ1 at the clinical level is limited by its short half-life, rapid clearance, and non-selective inhibition of BET family proteins, leading to off-target effects and resistance. To address these challenges, the optimization of JQ1 delivery has been accomplished through polylactide (PLA) nanoparticles. PLA derivatives with varying molecular weights were synthesized via ring-opening polymerization using a zinc-based initiator and characterized using thermogravimetric analysis, differential scanning calorimetry, and infrared spectroscopy.
View Article and Find Full Text PDFInt J Antimicrob Agents
January 2025
Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China; Research ward, Huashan Hospital, Fudan University, Shanghai, China. Electronic address:
Development of neutralizing monoclonal antibody (nAb) is a strategy for treatment of infections caused by SARS-CoV-2. This study evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) of HFB30132A, a fully human nAb targeting SARS-CoV-2 spike protein receptor binding domain, in healthy subjects. Randomized, double-blind, placebo-controlled phase I trial was performed in healthy Chinese and US subjects, respectively.
View Article and Find Full Text PDFPLoS Pathog
January 2025
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America.
The latent viral reservoir remains the major barrier to HIV cure, placing the burden of strict adherence to antiretroviral therapy (ART) on people living with HIV to prevent recrudescence of viremia. For infants with perinatally acquired HIV, adherence is anticipated to be a lifelong need. In this study, we tested the hypothesis that administration of ART and viral Envelope-specific rhesus-derived IgG1 monoclonal antibodies (RhmAbs) with or without the IL-15 superagonist N-803 early in infection would limit viral reservoir establishment in SIV-infected infant rhesus macaques.
View Article and Find Full Text PDFEJNMMI Res
January 2025
Department of Radiology & Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, the Netherlands.
Background: To study the feasibility of hepatobiliary scintigraphy (HBS) to improve selection and planning of patients with hepatocellular carcinoma (HCC) treated with holmium-166 (Ho)-microspheres radioembolization.
Results: Thirty-one patients with HCC were included and treated with Ho- radioembolization as part of a prospective phase 2 study. Twenty-seven patients were eligible for analysis, 67% had a cirrhotic liver morphology on imaging, 70% had multifocal disease and 51% had bilobar disease.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!